Best response, intent-to-treat population
| . | Arm 1: CHAM (n = 98) . | Arm 2: control (n = 102) . |
|---|---|---|
| Best response assessment∗ | ||
| CR | 20 (20.4%) | 22 (21.6%) P = .58 |
| CRi | 8 (8.2%) | 11 (10.8%) P = .53 |
| (CRh) | 1 (1.0%) | 0 (0%) |
| (CRMRD−) | NA | 1 (1.0%) |
| Morphologic leukemia-free state | 2 (2.0%) | 2 (2.0%) |
| PR | 6 (6.1%) | 5 (4.9%) |
| SD | 9 (9.2%) | 2 (2.0%) |
| PD | 16 (16.3%) | 14 (13.7%) |
| Relapse | - | 2 (2.0%) |
| Not evaluable† | 10 (10.2%) | 16 (15.7%) |
| . | Arm 1: CHAM (n = 98) . | Arm 2: control (n = 102) . |
|---|---|---|
| Best response assessment∗ | ||
| CR | 20 (20.4%) | 22 (21.6%) P = .58 |
| CRi | 8 (8.2%) | 11 (10.8%) P = .53 |
| (CRh) | 1 (1.0%) | 0 (0%) |
| (CRMRD−) | NA | 1 (1.0%) |
| Morphologic leukemia-free state | 2 (2.0%) | 2 (2.0%) |
| PR | 6 (6.1%) | 5 (4.9%) |
| SD | 9 (9.2%) | 2 (2.0%) |
| PD | 16 (16.3%) | 14 (13.7%) |
| Relapse | - | 2 (2.0%) |
| Not evaluable† | 10 (10.2%) | 16 (15.7%) |
P values calculated by Pearson χ2 test.
CRh, CR with partial hematologic recovery; CRi, CR with incomplete recovery; CRMRD−, CR without minimal residual disease; PD, progressive disease; PR, partial remission; SD, stable disease. NA, Not available.
If there are multiple response assessments, the best one was chosen, with priority to the categories in the order listed.
Not evaluable are patients who discontinued before post-baseline response assessments.